Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.9552W HIGH $12.94
Volume
15.33 K
Value Traded
469.17 K
Short % Float
3.44%
-4.5%Week
-16.18%1 Month
+9.45%3 Month
+7.6%6 Month
-23.01%5 Year
+92.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
78.26 M
EPS (TTM)
2.82
P/E Ratio
2.26
Ent. Value
64.70 M
Total Shares
12.29 M
Float Shares
9.84 M
Insiders
19.90%
Institutions
45.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LNSR Catalyst Timeline
Dated clinical, regulatory and corporate events for LENSAR, Inc.
Past FDA Catalysts and PDUFA Decisions
How LNSR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
LENSAR, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every LNSR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Connaughton Alan B.Officer (Chief Operating Officer) | Disposition | -2,739 354,330 held | $5.39 | 05/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LNSR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LNSR for Q2 2026. | ||||
LNSR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LNSR ranks across every disease it competes in
Competitive Position is a premium feature
See how LNSR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLNSR News
LNSR▲ +31.5%on this news
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
LENSAR, Inc. reported strong financial results for Q2 2026, with significant growth in revenue and recurring revenue compared to the previous year. The company placed 10 new ALLY Systems, increasing its installed base to 445. Despite a decrease in cash reserves, LENSAR achieved positive net income and strong Adjusted EBITDA, reflecting a solid business model and demand for its products.
Read more →LNSRLENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
LENSAR, Inc. announced that it will release its second quarter 2026 financial results on August 13, 2026. The company will host a conference call at 8:30 am ET to discuss these results and provide updates on corporate initiatives. LENSAR specializes in advanced robotic laser solutions for cataract treatment.
Read more →LNSR▲ +7.8%on this news
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
LENSAR, Inc. reported its first quarter 2026 results, revealing a total revenue of $13.4 million, a 5% decrease from the previous year. Despite this, the company saw a 39% growth in ALLY System placements and a 12% increase in its total installed base. Management remains optimistic about future growth in recurring revenue as market uncertainties lessen.
Read more →LNSRLENSAR® to Report First Quarter 2026 Results on May 8, 2026
LENSAR, Inc. will release its first quarter 2026 financial results on May 8, 2026. The company will host a conference call and webcast at 8:30 am ET to discuss these results and provide updates on corporate initiatives. The ALLY Robotic Cataract Laser System™ is a key product aimed at enhancing cataract surgery.
Read more →LNSRLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
LENSAR, Inc. reported its financial results for Q4 and full year 2025, highlighting a 48% growth in its ALLY installed base and a 15% increase in recurring revenue. Despite a slight decline in total revenue for Q4, the company experienced a significant rise in worldwide procedure volume. The management emphasized a commitment to advancing robotic laser cataract surgery following the termination of a merger agreement with Alcon.
Read more →LNSR▼ -32.8%on this news
LENSAR Announces Termination of Merger Agreement with Alcon Research, LLC Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026
LENSAR, Inc. has announced the termination of its merger agreement with Alcon Research, LLC, citing regulatory challenges from the Federal Trade Commission. The companies mutually agreed that proceeding with the merger was not in their best interests due to regulatory approval uncertainties. Despite this setback, LENSAR remains focused on its ALLY Robotic Cataract Laser System and plans to report its fourth quarter financial results on March 31, 2026. The company aims to advance its technology and market share in the cataract surgery field, although the termination may impact its business operations and relationships.
Read more →LNSRLENSAR® Provides Update on Pending Acquisition by Alcon
LENSAR, Inc. has provided an update on its pending acquisition by Alcon Research, LLC, indicating cooperation with the FTC for regulatory review. The company anticipates closing the transaction in the first half of 2026, contingent upon satisfying closing conditions. However, there are risks associated with regulatory approvals and potential delays.
Read more →LNSR▼ -8.6%on this news
LENSAR® Reports Third Quarter 2025 Results and Provides Business Update
LENSAR, Inc. reported a 6% increase in revenue for Q3 2025, totaling $14.3 million, driven by an 11% rise in procedure volume. The company placed 18 ALLY Systems, boosting its installed base by 77% year-over-year. However, net losses increased to $3.7 million, largely due to costs associated with the pending acquisition by Alcon. The company anticipates closing the merger in Q1 2026.
Read more →LNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. announced the grant of 660 restricted stock units (RSUs) to three newly-hired non-executive employees as an inducement for their employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of LENSAR's strategy to attract talent. The RSUs will vest over four years, contingent on continued service.
Read more →LNSRLENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems ( ALLY Systems ) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025
LENSAR, Inc. reported its second quarter 2025 financial results, highlighting a 107% growth in the installed base of its ALLY robotic cataract laser systems and a 23% increase in worldwide procedure volumes compared to the same period in 2024. The proposed merger with Alcon has progressed, with over 99% of stockholder votes in favor, and the company expects closure by year-end. Despite a revenue increase of 10% to $13.9 million, the company posted a net loss of $1.8 million due to rising operational costs.
Read more →LNSRLENSAR Reports First Quarter 2025 Results and Provides Business Update
LENSAR, Inc. reported solid financial results for the first quarter of 2025, with significant increases in revenue and procedure volumes compared to the previous year. The company placed 14 ALLY Robotic Laser Cataract Systems, reflecting a growing operational base. However, LENSAR also noted an increase in net losses driven by changes in warrant liability and higher expenses tied to the proposed merger with Alcon Research. The company aims to enhance its market position through this strategic acquisition.
Read more →LNSRAlcon Agrees to Acquire LENSAR, Inc.
Alcon has announced its intention to acquire LENSAR for $14.00 per share, totaling approximately $356 million, with potential additional payments based on performance milestones. This acquisition aims to integrate LENSAR's advanced laser technologies into Alcon's offerings, enhancing its capabilities in cataract surgery. The deal is expected to close in mid-to-late 2025, pending regulatory and stockholder approvals.
Read more →LNSR▲ +14.8%on this news· ran to +48% by day 3shared move
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
LENSAR, Inc. announced its financial results for Q4 and FY 2024, highlighting a strong performance with a total revenue increase of 27% over 2023. The company placed 31 ALLY systems in Q4, contributing to an annual total of over 80 placements and a notable 23% rise in recurring revenue. However, LENSAR faced challenges, reporting a significant net loss of $31.4 million for the year predominantly due to changes in warrant liability and an impairment charge. Despite the losses, LENSAR achieved over 20% market share in the U.S. procedure market for the first time in its history.
Read more →LNSRLENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
LENSAR, Inc. will release its fourth quarter and full year 2024 financial results on February 27, 2025. A conference call and webcast will follow at 8:30 am ET to discuss these results and recent corporate highlights. The company specializes in advanced robotic laser solutions for cataract treatment, enhancing operational efficiencies in surgical settings.
Read more →About LENSAR, Inc.
Headquarters2800 DISCOVERY DRIVE, ORLANDO, FL, 32826
BIOPHARMAWATCH ELITE PLUS
Trade the next LNSR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime